What happened
Abbott Laboratories has agreed to pay $384,999,040 to settle allegations that it caused false claims to be submitted to federal and state programmes between January 1, 2018 and December 31, 2022. The claims arise from Abbott's failure to manufacture certain powder infant formula and nutritional therapy products at its Sturgis, Michigan and Casa Grande, Arizona facilities in line with federal and state statutory, regulatory and contractual requirements, the Justice Department said.
Compliance Week reports that whistleblowers brought the allegations first. Three of them will share roughly $69 million, with close to $349 million of the settlement going to the federal government and just over $36 million to the state Medicaid and WIC programmes that bought the formula.
The United States filed its complaint in intervention on November 13, 2025. It alleged that Abbott knowingly manufactured infant formula purchased with taxpayer money in an environment that put the products at unacceptable risk of microorganism contamination. Reporting on the complaint describes umbrellas set up to manage roof leaks, which diverted water away from production areas but created a wet environment suited to bacterial growth, and a lengthening of the number of product batches run through the spray dryers between cleaning cycles so that output could increase. The complaint also alleged that Abbott did not test for bacterial growth in order to avoid positive results, and that where testing did find "micro" contamination, the company failed to disclose it.
"No company should be gambling on the health and safety of our Nation's infants by allowing unsanitary conditions to persist at a facility manufacturing baby formula," said Associate Attorney General Stanley E. Woodward, Jr.
U.S. Attorney Timothy VerHey for the Western District of Michigan said the settlement shows the department's commitment to holding manufacturers accountable when the United States pays for noncompliant products. The underlying facts trace back to the 2022 recall and the temporary shutdown of the Sturgis plant, which fed into a national formula shortage. The Justice Department closed a criminal probe into Abbott's handling of the plant earlier this year and pursued civil penalties instead.
Why this is a GRC story
The theory here is not that Abbott broke a food safety rule. It is that the company certified compliance in order to be paid, and could not produce the evidence behind that certification. That is the shape of most false claims cases, and it pulls manufacturing quality, testing and documentation into the compliance perimeter.
The specific allegations point to named controls: change control on cleaning cycles, environmental monitoring design, and the escalation and disclosure of adverse test results. Each of those carries a documented obligation and a signature somewhere, which makes each one testable rather than aspirational.
Silence about unfavourable test results is the recurring theme in quality and safety enforcement. A control design that stops bad news travelling to the people who decide things is a governance defect, not only a quality one, and it is exactly the pattern a whistleblower suit is built to expose.
The financial structure matters too. Awards at this scale keep qui tam litigation funded, and they put internal records in front of the department on a timetable the company does not control.
What to watch
Watch for any compliance obligations written into the settlement itself, and whether the department and the FDA keep running parallel investigations over the same facts.
Watch the remediation work at both plants. The transferable lesson: if a metric can deteriorate and nobody is obliged to report it upward, assume it is being managed quietly.
Attribution: Analysis based on Compliance Week, the Department of Justice announcement, and related public reporting. This article is original commentary, not a repost of the source material.